Monitoring CAR T cells in peripheral blood by flow cytometry following Tisagenlecleucel in Fundeni Clinical Institute, Bucharest
By:
References
- Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019 May;94(S1):S3-9. DOI: 10.1002/ajh.25418
- Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N Engl J Med. 2021 Aug 5;385(6):567-9. DOI: 10.1056/NEJMc2107725
- Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020 Mar;17(3):147-67. DOI: 10.1038/s41571-019-0297-y
- Jensen MC, Riddell SR. Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol. 2015 Apr;33:9-15. DOI: 10.1016/j.coi.2015.01.002
- Fujiwara K, Tsunei A, Kusabuka H, Ogaki E, Tachibana M, Okada N. Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold. Cells. 2020 May 9;9(5):1182. DOI: 10.3390/cells9051182
- Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014 Jan;257(1):107-26. DOI: 10.1111/imr.12131
- Gerdemann U, Christin AS, Vera JF, Ramos CA, Fujita Y, Liu H, et al. Nucleofection of DCs to Generate Multivirus-specific T Cells for Prevention or Treatment of Viral Infections in the Immunocompromised Host. Mol Ther. 2009 Sep 1;17(9):1616-25. DOI: 10.1038/mt.2009.140
- FDA approves axicabtagene ciloleucel for large B-cell lymphoma. FDA [Internet]. 2019 Feb 9 [cited 2023 Apr 19]; Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-axicabtagene-ciloleucel-large-b-cell-lymphoma
- FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. FDA [Internet]. 2019 Feb 9 [cited 2023 Apr 19]; Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisagenlecleucel-b-cell-all-and-tocilizumab-cytokine-release-syndrome
- Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering. Nature. 2017 May;545(7655):423-31. DOI: 10.1038/nature22395
- Kawalekar OU, O’Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, et al. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity. 2016 Feb 16;44(2):380-90. DOI: 10.1016/j. immuni.2016.01.021
- Philipson BI, O’Connor RS, May MJ, June CH, Albelda SM, Milone MC. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling. Sci Signal. 2020 Mar 31;13(625):eaay8248. DOI: 10.1126/scisignal.aay8248
- Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020 Nov 10;4(21):5414-24. DOI: 10.1182/bloodadvances.2020003092
- Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol. 2012 Feb 17;12(3):191-200. DOI: 10.1038/nri3158
- Miltenyi Biotec. CD19 CAR Detection Reagent Protocol [Internet]. Available from: https://www.miltenyibiotec.com/upload/assets/IM0028385.PDF
- BD Biosciences. BD Biosciences TBNK Instructions For Use [Internet]. Available from: https://www.bdbiosciences.com/content/dam/bdb/products/global/reagents/flow-cytometryreagents/clinical-diagnostics/multicolor-cocktails-and-kits-ivdce-ivds/662967_base/pdf/23-19817.pdf
- Demaret J, Varlet P, Trauet J, Beauvais D, Grossemy A, Hégo F, et al. Monitoring CAR T-cells using flow cytometry. Cytometry B Clin Cytom. 2021 Mar;100(2):218-24. DOI: 10.1002/cyto.b.21941
- Peinelt A, Bremm M, Kreyenberg H, Cappel C, Banisharif-Dehkordi J, Erben S, et al. Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following Tisagenlecleucel. Front Immunol. 2022;13:830773. DOI: 10.3389/fimmu.2022.830773
- Blache U, Weiss R, Boldt A, Kapinsky M, Blaudszun AR, Quaiser A, et al. Advanced Flow Cytometry Assays for Immune Monitoring of CAR T Cell Applications. Front Immunol [Internet]. 2021 [cited 2023 Apr 19];12. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2021.658314 DOI: 10.3389/fimmu.2021.658314
- Kochenderfer JN, Somerville RPT, Lu T, Yang JC, Sherry RM, Feldman SA, et al. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. Mol Ther J Am Soc Gene Ther. 2017 Oct 4;25(10):2245-53. DOI: 10.1016/j.ymthe.2017.07.004
- Liu Q, Sun Z, Chen L. Memory T cells: strategies for optimizing tumor immunotherapy. Protein Cell. 2020 Aug;11(8):549-64. DOI: 10.1007/s13238-020-00707-9
- Busch DH, Fräßle SP, Sommermeyer D, Buchholz VR, Riddell SR. Role of memory T cell subsets for adoptive immunotherapy. Semin Immunol. 2016 Feb;28(1):28-34. DOI: 10.1016/j. smim.2016.02.001
- Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018 Oct;24(10):1499-1503. DOI: 10.1038/s41591-018-0201-9
- Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med. 2014 Oct 16;371(16):1507-17. DOI: 10.1056/NEJMoa1407222
Language: English
Page range: 175 - 184
Submitted on: Apr 27, 2023
Accepted on: Jun 28, 2023
Published on: Jul 28, 2023
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2023 Delia C. Popa, Horia M. Sandu, Raluca Suciu, Valeria G. Ţica, Andreea Şerbănică, Ionut Şerbănică, Cristina Jercan, Daniel Coriu, Alina Tanase, Anca Coliţă, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution 4.0 License.